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Peroxisome proliferator-activated receptor (PPAR)α is mainly expressed in the liver 28 
and plays an important role in the regulation of lipid metabolism. It has been reported 29 
that PPARα activation enhances fatty acid oxidation and reduces fat storage. Therefore, 30 
PPARα agonists are used to treat dyslipidemia. In the present study, we found that 31 
9-oxo-10(E),12(Z),15(Z)-octadecatrienoic acid (9-oxo-OTA), which is α-linolenic acid 32 
(ALA) derivative, is present in tomato (Solanum lycopersicum) extract. We showed that 33 
9-oxo-OTA activated PPARα and induced the mRNA expression of PPARα target genes 34 
in murine primary hepatocytes. These effects promoted fatty acid uptake and the 35 
secretion of β-hydroxybutyrate, which is one of the endogenous ketone bodies. We also 36 
demonstrated that these effects of 9-oxo-OTA were not observed in PPARα-knockout 37 
(KO) primary hepatocytes. To our knowledge, this is the first study to report that 38 
9-oxo-OTA promotes fatty acid metabolism via PPARα activation and discuss its 39 
potential as a valuable food-derived compound for use in the management of 40 
dyslipidemia. 41 
 42 




Dyslipidemia, which results from obesity, is a recognized risk factor for serious 47 
disorders, including arteriosclerosis, hyperlipidemia, hepatic steatosis, insulin resistance, 48 
and cardiovascular disease [1-4]. Therefore, avoidance of dyslipidemia is important to 49 
help prevent these lifestyle diseases. 50 
Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated 51 
transcription factors [5-9] comprised of three isoforms PPARα, PPARβ/δ, and PPARγ. 52 
PPARα is very important in the regulation of lipid metabolism [5-7] and is expressed at 53 
high levels in the liver where it promotes β-oxidation, ketogenesis, and lipid transport 54 
[10, 11]. PPARα activation induces the expression of PPARα-regulated genes (e.g., 55 
carnitine-O-palmitoyltransferase 1 [CPT] and acyl-CoA oxidase [ACO]) and activates 56 
β-oxidation [12-14]. These effects result in increased energy expenditure and reduced 57 
fat storage [15]. It has been reported that PPARα activation enhances fatty acid 58 
metabolism and decreases the levels of circulating and cellular lipids in obese diabetic 59 
patients [9, 16]. Therefore, regulation of PPARα activity is one of the important ways to 60 
manage chronic diseases related to lipid metabolism dysfunction. 61 
Tomato (Solanum lycopersicum) is one of the most extensively consumed crops 62 
worldwide. Numerous studies have shown that dietary tomato intake is associated with 63 
a reduced risk of chronic diseases [17–20]. Recently, we reported that tomatoes contain 64 
the oxidized linoleic acid (LNA) derivatives 9-oxo-10,12-octadecadienoic acid 65 
(9-oxo-ODA) and 13-oxo-9,11-octadecadienoic acid (13-oxo-ODA), which can 66 
function as PPARα agonists [21,22]. Oxo-ODAs are oxylipins, which include fatty acid 67 
hydroperoxides, hydroxyl-, oxo-, epoxy, and keto fatty acids, divinyl ethers, aldehydes, 68 
and jasmonic acid [23]. Tomato is believed to contain not only oxo-ODAs but also 69 
many other beneficial oxylipins that enhance lipid metabolism and suppress diseases 70 
such as arteriosclerosis, hyperlipidemia, and hepatic steatosis. 71 
The aim of the present study was to identify the metabolite in tomato that enhances 72 
fatty acid metabolism and to determine its mechanism of action. In the present study, we 73 
showed that 9-oxo-10(E),12(Z),15(Z)-octadecatrienoic acid (9-oxo-OTA), which is a 74 
derivative of α-linolenic acid (ALA), is present in tomato fruit extract. We showed that 75 
9-oxo-OTA activates PPARα and induces the mRNA expression of PPARα target genes, 76 
which promotes fatty acid metabolism in murine hepatocytes. To the best of our 77 
knowledge, this is the first study to report that 9-oxo-OTA induces fatty acid 78 
metabolism through PPARα activation, and our findings suggest that 9-oxo-OTA could 79 
be a valuable food-derived compound capable of improving dyslipidemia. 80 
81 
Materials and methods 82 
Materials 83 
Authentic 9-oxo-OTA was purchased from Cayman Chemicals (Ann Arbor, MI, 84 
USA). Authentic cis-10-heptadecenoic acid (HDA), which was used as an internal 85 
standard, was purchased from Sigma (St. Louis, MO, USA). All other chemicals were 86 
obtained from Sigma or Wako (Osaka, Japan). Buffers used were of high-performance 87 
liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS) 88 
grade. Tomatoes were obtained from a local market. 89 
 90 
Analysis of 9-oxo-OTA by ultra-performance liquid chromatography-quadrupole 91 
time-of-flight mass spectrometry (UPLC-QTOF-MS) 92 
The levels of 9-oxo-OTA were assessed as previously described, using a LC-MS 93 
system [24]. Briefly, each freeze-dried tomato (10 mg) was homogenized in 1 mL of 94 
extraction solvent (99.5% EtOH containing 1 µg/mL HDA) with a mixer. After 95 
centrifugation (15,000 rpm, 10 min, 4°C), the supernatant was collected for use as an 96 
extract. The extract was filtered through a 0.2-µm-pore polyvinylidene difluoride 97 
(PVDF) membrane (Whatman, Brentford, UK), and the filtrate was used for LC-MS. 98 
LC-MS was performed using a Waters Acquity UPLC system (Milford, MA) 99 
coupled to a Xevo QTOF-MS equipped with an electrospray source operating in 100 
negative ion mode (ESI negative mode), with a lock-spray interface for accurate mass 101 
measurements. Leucine enkephalin was employed as the lock-mass compound. It was 102 
infused directly into the MS at a flow rate of 30 µL/min and a concentration of 200 103 
µg/mL (in 50% acetonitrile, 50% water, 0.1% formic acid). The capillary, sampling cone, 104 
and extraction cone voltages were set at 2700 V, 20 V, and 1 V, respectively. The source 105 
and desolvation temperatures were 120°C and 450°C, respectively. The cone and 106 
desolvation gas flow rates were set at 50 and 800 L/h, respectively. 107 
An aliquot of the extracted sample (3 µL) was injected into an Acquity UPLC 108 
BEH-C18 reversed-phase column (column size, 2.1 × 100 mm; particle size, 1.7 µm). 109 
Mobile phases A (water and 0.1% formic acid) and B (acetonitrile and 0.1% formic 110 
acid) were used. The column temperature was set to 40°C. The buffer gradient consisted 111 
of 30% to 50% B for 0–4 min, 50% to 85% B for 4–14 min, 99% B for 14–17 min, and 112 
30% B for 3 min, at a flow rate of 300 µL/min. Data were acquired with MassLynx 113 
software (Waters). External mass calibration was performed following the 114 
manufacturer’s protocol. 115 
 116 
Analysis of β-hydroxybutyrate by UPLC-QTOF-MS 117 
The medium from a culture of primary hepatocytes (50 µL) was mixed with 50 µL 118 
of acetonitrile. After centrifugation (15,000 rpm, 10 min, 4°C), the supernatant was 119 
collected for use as an as an extract. The extract was filtered through a 0.2-µm-pore 120 
polyvinylidene difluoride (PVDF) membrane (Whatman), and the filtrates were used for 121 
LC-MS. 122 
In the MS system, the capillary, sampling cone, and extraction cone voltages were 123 
set at 2600 V, 15 V, and 3 V, respectively (ESI negative mode). The source and 124 
desolvation temperatures were 120°C and 450°C, respectively. The cone and 125 
desolvation gas flow rates were set at 50 and 800 L/h, respectively. 126 
We used a BEH Amide column (column size, 2.1 × 100 mm; particle size, 1.7 µm). 127 
The column temperature was set to 40°C. The buffer gradient consisted of 95% B for 128 
0–4 min, 95% to 50% B for 4–10 min, 50% B for 10–16 min, and 95% B for 4 min, at a 129 
flow rate of 300 µL/min. Data were acquired with MassLynx software (Waters). 130 
 131 
Luciferase assay 132 
Luciferase assays were performed as previously described, using a GAL4/PPAR 133 
chimera system [25]. We transfected p4xUASg-tk-luc (a reporter plasmid), 134 
pM-hPPARa (an expression plasmid for a chimeric protein containing the GAL4 135 
DNA-binding domain and each human PPAR-ligand-binding domain), and pRL-CMV 136 
(an internal control for transfection efficiency) into monkey CV1 kidney cells by using 137 
Lipofectamine (Life Technologies Japan Ltd.) according to the manufacturer’s protocol. 138 
Luciferase activity was assayed using the dual luciferase system (Promega, Madison, 139 
WI, USA) according to the manufacturer’s protocol. 140 
 141 
Preparation of mouse primary hepatocytes 142 
All the animal experiments were approved by the Kyoto University Animal Care 143 
Committee. C57BL/6J male mice (wild type and PPARα-/-, free-feed) were anesthetized 144 
with intraperitoneal administration of pentobarbital, and the liver was perfused with 145 
liver perfusion medium (Life Technologies Japan Ltd.). Then, the liver was treated with 146 
liver digestion medium (Life Technologies Japan Ltd.). After filtration through a 147 
100-µm nylon mesh filter, hepatocytes were isolated by repeated centrifugation at 50 × 148 
g for 3 min (3 times). The isolated hepatocytes were cultured in type-1 collagen-coated 149 
12-well plates at a cell density of 2.0 × 105 cells/well. After a 5-h incubation at 37°C in 150 
5% CO2 in 20% serum DMEM (1.0g/L glucose), the hepatocytes were cultured in 151 
serum-free DMEM (1.0g/L glucose) with or without 9-oxo-OTA for 5 h (mRNA assay) 152 
or 8 h (LC-MS and RI assay), and then used for mRNA quantification and LC-MS 153 
assays. 154 
 155 
Quantification of mRNA expression levels 156 
Total RNA was prepared from primary hepatocytes using Sepasol (Nacalai Tesque), 157 
according to the manufacturer’s protocol. Using M-MLV reverse transcriptase (Life 158 
Technologies Japan Ltd.), total RNA was reverse transcribed. To determine mRNA 159 
expression levels, real-time quantitative RT-PCR analysis was performed with a Light 160 
Cycler System (Roche Diagnostics) using SYBR green fluorescence signals as 161 
described previously [25, 26]. The oligonucleotide primer sets for mouse 36B4 (internal 162 
control) and the PPARα target genes were designed using a PCR primer selection 163 
program on the website of the Virtual Genomic Center at GenBank and the sequences 164 
are shown in Table 1. All mRNA expression data are presented as ratios relative to the 165 
control in each experiment. 166 
 167 
Measurement of 14C-Palmitic acid uptake and 14CO2 production in murine 168 
primary hepatocytes 169 
These experiments were conducted as previously described with some modifications 170 
[27-29]. In the measurement of 14C-palmitic acid uptake, the cells were washed with 171 
PBS (500 µL/well) and then incubated in assay buffer (14C-palmitic acid, 2 µCi/well; 172 
fatty acid free BSA, 2.5%; and normal palmitic acid, 200 µM) for 3 min at room 173 
temperature (1 mL/well). The experiment was stopped by washing the cells 3 times with 174 
PBS (500 µL/well). The cells were lysed in 0.1% Triton-X solution (200 µL/well). The 175 
radioactivity in the cell lysate was counted for 1 min in 2 mL of scintillation solution to 176 
measure fatty acid uptake. In the measurement of 14CO2 production, mice primary 177 
hepatocytes were incubated in assay buffer (DMEM containing 14C-palmitic acid, 2 178 
µCi/well; glucose, 1.0g/L; L-carnitine, 200 µM ; fatty acid free BSA, 2.5%; and normal 179 
palmitic acid, 200 µM) for 8h. The medium was transferred to a 50-mL tube. An 180 
uncapped-2mL sample tube containing a piece of filter paper soaked in 0.1N NaOH was 181 
placed inside a 50-mL tube. After the tube was sealed, 200µL of 70% perchloric acid 182 
was added to the medium sample to release 14CO2. The saturated filter paper containing 183 
trapped 14CO2 was assessed for radioactivity in a liquid scintillation counter (LS6500, 184 
Beckman Coulter, CA, USA). 185 
 186 
Statistical analyses 187 
Data are presented as mean ± standard error of the mean (SEM). Differences 188 
between groups were compared with the Student’s t-test (for two groups) and one-way 189 
analysis of variance (ANOVA) followed by Tukey’s test. P values less than 0.05 were 190 
considered statistically significant. 191 
192 
Results 193 
Identification of 9-oxo-OTA in tomato fruit extract 194 
First, we explored the oxylipins, which are metabolized from ALA in plants (Fig. 1), 195 
in the tomato extract using LC-MS. The results showed that the extract of tomato fruit 196 
homogenate obtained under heating (37 °C, 30 min) contained 9-oxo-OTA (Fig. 2 A; Rt 197 
= 7.91 min, m/z = 291.20, Fig. 2 B, C). The 9-oxo-OTA peak was detected as an 198 
unfragmented deprotonation ion (C18H27O3
-, [M-H]-, Fig. 2 C) by electrospray negative 199 
ionization mass spectrometry. In the tandem mass spectrometry (MS/MS) data, we 200 
confirmed that the fragment ion detected in the tomato extract (m/z = 185, 125, and 201 
121) matched the pure 9-oxo-OTA sample (Fig. 2D). 202 
Quantitative analysis of the 9-oxo-OTA content in each part of the tomato fruit 203 
homogenate under liquid nitrogen (gelatinous tissue: low limit of quantification 204 
(LLOQ), sarcocarp: LLOQ, peel: LLOQ; Table 2) or heating (gelatinous tissue: 205 
approximately 0.46 µg/g of tissue weight, sarcocarp: 0.23 µg/g of tissue weight, peel: 206 
0.62 µg/g of tissue weight; Table 2) revealed that the amount of 9-oxo-OTA in all 207 
tissues was increased by heat treatment. 208 
 209 
9-oxo-OTA activated PPARα and induced the mRNA expression of PPARα target 210 
genes 211 
9-oxo-OTA is analogous to 9-oxo-10,12-octadecadienoic acid (9-oxo-ODA, Fig. 1) 212 
and 13-oxo-9,11,15-octadecatrienoic acid (13-oxo-OTA, Fig. 1). In our previous studies 213 
showed that 9-oxo-ODA is involved in PPARα activation [22] and 13-oxo-OTA 214 
activates PPARγ [24]. Therefore, we hypothesized that 9-oxo-OTA activates PPARα 215 
and/or PPARγ. To determine the effect of 9-oxo-OTA on PPARα and PPARγ activity, we 216 
first performed a luciferase ligand assay. In the PPARα activation level, 9-oxo-OTA was 217 
stronger than 13-oxo-OTA (Fig. 3 A). In the PPARγ activation level, 13-oxo-OTA was 218 
stronger than 9-oxo-OTA (Fig. 3 B). We also showed that 9-oxo-OTA increased 219 
luciferase activity in a time dependent manner (Fig. 3 C), and this luciferase activity 220 
was inhibited by PPARα antagonist (GW6471) treatment (Fig. 3 D). PPARα is 221 
expressed in liver where it promotes β-oxidation, ketogenesis, and lipid transport [10, 222 
11] and important in the regulation of lipid metabolism [5-7]. To elucidate the 223 
contribution of 9-oxo-OTA to lipid metabolism in hepatocytes, murine hepatocytes were 224 
cultured in medium containing 9-oxo-OTA. In murine hepatocytes, we showed that the 225 
expression of PPARα mRNA was increased by 9-oxo-OTA treatment (approximately 226 
1.8-fold, Fig. 4 A). Furthermore, the mRNA expression levels of PPARα target genes, 227 
such as Cpt1a, Acs, Hmgcs2, and Cd36, were increased by 9-oxo-OTA treatment 228 
(approximately 1.5-fold, 1.4-fold, 1.5-fold, and 1.4-fold, respectively, Fig. 4 B–E). We 229 
also demonstrated that the 9-oxo-OTA-mediated effect on PPARα target gene 230 
expression was not observed in PPARα-KO primary hepatocytes (Fig. 4 B–E). These 231 
findings suggest that 9-oxo-OTA promotes the mRNA expression of the genes involved 232 
in fatty acid oxidation via PPARα activation. 233 
 234 
9-oxo-OTA promoted fatty acid oxidation in primary hepatocytes 235 
PPARα is the major regulator of fatty acid metabolism [5-7], suggesting that 236 
9-oxo-OTA induces fatty acid oxidation via PPARα activation. We investigated whether 237 
9-oxo-OTA influences not only mRNA expression levels but also lipid metabolism. The 238 
results showed that 14C-palmitic acid uptake was increased by 9-oxo-OTA treatment 239 
(approximately 1.4-fold, Fig. 5 A), suggesting enhanced fatty acid metabolism. We also 240 
showed that 14CO2 production was increased by 9-oxo-OTA treatment (approximately 241 
1.5-fold, Fig. 5 B). β-Oxidation is one of the primary modes of fatty acid metabolism, 242 
which converts fatty acids to ketone bodies. β-hydroxybutyrate, which is one of the 243 
ketone bodies, is an important marker of fatty acid oxidation. We investigated whether 244 
9-oxo-OTA effects the production of β-hydroxybutyrate in murine primary hepatocytes 245 
and demonstrated that β-hydroxybutyrate secretion was increased by 9-oxo-OTA 246 
treatment (approximately 1.5-fold, Fig. 5 C). The enhancement of fatty acid uptake and 247 
secretion of 14CO2 and β-hydroxybutyrate induced by 9-oxo-OTA were not observed in 248 
PPARα-KO primary hepatocytes (Fig. 5). These findings suggest that 9-oxo-OTA 249 




In the present study, we analyzed the metabolites in tomato extract by using LC-MS 254 
and identified 9-oxo-OTA. Our previous study showed that ALA, which is a 255 
9-oxo-OTA precursor, was present in tomato extracts [30]. These data suggested that 256 
9-oxo-OTA can be derived from ALA via a non-enzymatic and/or enzymatic reaction. It 257 
is possible that ALA is susceptible to oxidation at C9 via auto-oxidation and/or 258 
lipoxygenase is involved in the production of 9-oxo-OTA in tomato fruits. Our previous 259 
study also revealed that 9-oxo-ODA is localized primarily in the fruit peel [30]. 260 
However, here we showed that 9-oxo-OTA exists in not only peel but also in the 261 
gelatinous tissue and sarcocarp. Further examinations are necessary to elucidate the 262 
differences in the localization of 9-oxo-OTA and 9-oxo-ODA. We also revealed that the 263 
amount of 9-oxo-OTA in tomato extract is increased by heating. This finding suggested 264 
that heat processing increases the amount of 9-oxo-OTA in processed tomato foods. 265 
Tomato fruit contains not only 9-oxo-OTA but also many other compounds. Therefore, 266 
it is difficult that the effect of tomato on fatty acid oxidation is explained by only 267 
9-oxo-OTA via PPARα dependent pathway. To evaluate 9-oxo-OTA in vivo, it is 268 
necessary to process selective breeding (tomato fruit having high 9-oxo-OTA content) 269 
and/or to improve processing condition (e.g. tomato juice having high 9-oxo-OTA 270 
content). 271 
PPARα is expressed principally in the liver, and it is a key regulator of various 272 
aspects of lipid metabolism, including β-oxidation, ketogenesis, and lipid transport [10, 273 
11]. PPARα agonists are used in the treatment of dyslipidemia [9, 16]. Although we 274 
previously reported that 9-oxo-ODA contributes to the activation of PPARα [21], little 275 
is known about the effect of 9-oxo-OTA on PPARα. The structure of 9-oxo-OTA is 276 
similar to that of 9-oxo-OTA. Therefore, we hypothesized that 9-oxo-OTA also has the 277 
ability to activate PPARα. 278 
Here, we demonstrated for the first time that 9-oxo-OTA activates PPARα in 279 
luciferase ligand assay. There is the possibility that 9-oxo-OTA activate PPARα both 280 
directly and/or indirectly. In case of the direct action, 9-oxo-OTA acts as PPARα ligand. 281 
In case of the indirect action, the metabolites of 9-oxo-OTA act as PPARα ligands. We 282 
also showed that 9-oxo-OTA increased the mRNA expression of Cpt1a, Acs, Hmgcs2, 283 
and Cd36, which are PPARα target genes that are involved in fatty acid metabolism 284 
[12-14, 31-33, 35-36]. These effects of 9-oxo-OTA on the expression of PPARα target 285 
genes were not observed in PPARα-KO primary hepatocytes. These findings suggested 286 
that 9-oxo-OTA promotes fatty acid metabolism in murine hepatocytes via a 287 
PPARα-dependent pathway. However, the expression of Cd36 was trend toward 288 
significance in PPARα-KO primary hepatocytes treated with 9-oxo-OTA. We confirmed 289 
that 9-oxo-OTA also activates PPARγ in luciferase ligand assay. It is well known that 290 
the expression of Cd36 is induced by not only PPARα but also PPARγ activation 291 
[34-36]. Therefore, there is the possibility that the effect of 9-oxo-OTA on PPARγ 292 
activation contributes to trend toward increment of Cd36 expression.  293 
Our present study also showed that the effect of 9-oxo-OTA on fatty acid oxidation 294 
occurs through alteration of not only mRNA expression levels but also metabolism. 295 
Fatty acids are taken up by hepatocytes primarily via CD36 [32]. We showed that fatty 296 
acid uptake was increased by 9-oxo-OTA treatment. This effect was not observed in 297 
PPARα-KO primary hepatocytes, suggesting that 9-oxo-OTA promotes fatty acid uptake 298 
via PPARα activation. We also showed that the mRNA expression level of Hmgcs2 299 
(3-hydroxy-3-methylglutaryl-CoA synthase 2) was increased by 9-oxo-OTA treatment. 300 
Hmgcs2 is the key enzyme involved in ketone body formation [33]. β-Hydroxybutyrate 301 
is a major component of ketone bodies and a marker of fatty acid oxidation. Therefore, 302 
we hypothesized that 9-oxo-OTA also promotes the production of β-hydroxybutyrate in 303 
murine hepatocytes. The LC-MS analysis revealed that β-hydroxybutyrate secretion 304 
from murine primary hepatocytes was increased by 9-oxo-OTA treatment. In the RI 305 
experiment using 14C-palmitic acid, we showed that 14CO2 production was increased by 306 
9-oxo-OTA treatment. The increment of 14CO2 production and β-hydroxybutyrate 307 
secretion suggest that 9-oxo-OTA promoted lipid metabolism in wild-type murine 308 
hepatocytes. In contrast, 9-oxo-OTA treatment decreased 14CO2 production and 309 
β-hydroxybutyrate secretion in PPARα-KO primary hepatocytes. Our present study is 310 
focused on the effect of 9-oxo-OTA on PPARα activation and its downstream targets. 311 
But, there is the possibility of the effect of 9-oxo-OTA on other pathways including 312 
PPARγ activation. The previous study showed that acetoacetyl-CoA synthetase (AACS) 313 
is a PPARγ target gene [37]. AACS is a ketone body-specific ligase and might play an 314 
important role in the provision of acetyl-CoA for lipogenesis [38]. 9-oxo-OTA activates 315 
both PPARα and PPARγ. In the PPARα KO hepatocytes treated with 9-oxo-OTA, there 316 
is the possibility that fatty acid oxidation via PPARα dependent pathway disappeared 317 
and lipogenesis proceed via PPARγ dependent pathway. In this study, we showed that 318 
9-oxo-OTA promotes fatty acid metabolism via PPARα activation and increases the 319 
expression of PPARα target genes in murine hepatocytes. Further examination is 320 
necessary to determine the effect of 9-oxo-OTA on human metabolism. 321 
In conclusion, 9-oxo-OTA contained in tomato fruit activates PPARα and induces 322 
the mRNA expression of PPARα target genes. This promotes fatty acid oxidation in 323 
murine hepatocytes. These findings provide the first evidence that 9-oxo-OTA induces 324 
fatty acid metabolism through a PPARα-dependent pathway and may contribute to the 325 
development of improved treatments for dyslipidemia patients. Our findings suggest 326 
that 9-oxo-OTA might be a valuable, food-derived compound for maintaining health. 327 
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 Figure legends 448 
Fig. 1. Oxo-OTAs, Oxo-ODAs and their precursors (fatty acids).  449 
 450 
Fig. 2. Identification of 9-oxo-10(E),12(Z),15(Z)-octadecatrienoic acid (9-oxo-OTA) 451 
by LC-MS. (A) The structure of 9-oxo-OTA. (B) Extracted ion chromatogram (m/z = 452 
291.20) data and (C) full mass data for 9-oxo-OTA in an authentic sample and a tomato 453 
extract sample. (D) MS/MS data for 9-oxo-OTA in an authentic sample and a tomato 454 
extract sample.  455 
 456 
Fig. 3. 9-oxo-OTA activated PPARα. (A) Effect of 9-oxo-OTA and 13-oxo-OTA 457 
(30µM respectively) on PPARα activity with a luciferase reporter assay. (B) Effect of 458 
9-oxo-OTA and 13-oxo-OTA (10µM respectively) on PPARγ activity with a luciferase 459 
reporter assay. (C) Effect of 9-oxo-OTA on PPARα activity in a dose-dependent manner. 460 
(D) Evaluation of PPARα activity with a luciferase reporter assay in cells treated with 461 
9-oxo-OTA (30 µM) and/or GW6471 (PPARα antagonist, 100 nM). Data are presented 462 
as mean ± SEM (n = 5). Symbol for p < 0.05 between the means of the 3 groups. OTA; 463 
9-oxo-OTA, GW; GW6471. 464 
 465 
Fig. 4. 9-oxo-OTA activated the expression of PPARα target genes in murine 466 
hepatocytes. Effect of 9-oxo-OTA (30 µM) on (A) PPARα expression levels in murine 467 
primary hepatocytes. Effect of 9-oxo-OTA (30 µM) on (B) Cpt1a, (C) Acs, (D) Hmgcs2, 468 
and (E) Cd36 expression in wild-type (WT) or PPARα-/- (KO) primary hepatocytes. 469 
Data are presented as mean ± SEM (n = 5–6). **p < 0.01, ***p < 0.001 vs. control. 470 
 471 
Fig. 5. 9-oxo-OTA promoted fatty acid metabolism in murine hepatocytes. (A) The 472 
uptake of 14C-palmitic acid and (B) 14CO2 production in murine WT or KO primary 473 
hepatocytes treated with 9-oxo-OTA (30 µM). (C) The secretion of β-hydroxybutyrate 474 
from murine WT or KO primary hepatocytes treated with 9-oxo-OTA (30 µM). Data are 475 
presented as mean ± SEM (n = 3–5). *p < 0.05, **p < 0.01 vs. control.  476 
Figure 1. Takahashi H, et al. 
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Figure 4. Takahashi H, et al. 































































































































































































































































































































































































































Table 1. Oligonucleotide primers used for mRNA analysis. 
gene forward primer reverse primer 
Pparα TCGCGTACGGCAATGGCTTT TCTTCATCCCCAAGCGTAGGAGG 
Cpt1a CTCAGTGGGAGCGACTCTTCA GGCCTCTGTGGTACACGACAA 
Acs ACATCCACGTGTATGAGTTCTACGC AGTAGACGAAGTTCTCACGGTCGAT 
Hmgcs2 AATCAGTGGAAGCAAGCTGGA GTCCAGGGAGGCCTTCAAAA 
Cd36 GATGTGGAACCCATAACTGGATTCAC GGTCCCAGTCTATTTAGCCACAGT 
36B4 TCCTTCTTCCAGGCTTTGGG GACACCCTCCAGAAAGCGAG 
Table 2. Quantitative analysis of 9-oxo-OTA in tomato fruit homogenate under 
liquid nitrogen or heating (at 37°C for 30 min; µg/g fresh weight). 
tissue liquid nitrogen heating 
gelatinous tissue LLOQ 0.46±0.10 
sarcocarp tissue LLOQ 0.23±0.05 
peel tissue LLOQ 0.62±0.12 
LLOQ: low limit of quantification. Data are presented as mean ± SEM (n = 3). 
 
 
